Recurrence of genitals warts in pre-HPV vaccine era after laser treatment.
Carbon dioxide laser
Genital warts
HPV
Human papilloma virus
Multifocal lesions
Recurrence
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
15
04
2019
accepted:
02
07
2019
pubmed:
10
7
2019
medline:
22
4
2020
entrez:
10
7
2019
Statut:
ppublish
Résumé
Human papillomavirus (HPV) can cause condylomata acuminata, also known as genital warts. Our aim was to evaluate the long-term recurrence of genital warts after primary carbon dioxide laser treatment before the introduction of the vaccination against HPV. Recurrence rate and localization of genital warts were analysed in a retrospective study in 1798 women presenting with a new diagnosis of genital warts from 1992 to 2009 at a University hospital and had received laser treatment. Additionally, data on topography, pregnancy status, and cervical smear were available for women treated from 2003 to 2009 (n = 825, data subset 1) and systematic follow-up data for women treated in 2006 and 2007 (n = 242, data subset 2). Median time from laser treatment to first recurrence was 14.6 weeks (data subset 2). The site most affected was the vulva (90.7%) followed by the perineum/perianal region (59.3%) and the vagina (47.3%). Abnormal Pap smear was observed in 22.6%. Systematic follow-up with a median follow-up time of 3.1 years revealed at least one recurrence in 68 (28.1%) of 242 women. Women with multifocal genital warts had a 2.9 times increased risk for recurrence compared to women with unifocal lesions (p = 0.01). Nearly 30% of women presenting with genital warts experienced at least one recurrence after treatment with carbon dioxide laser. Multifocal lesions are the strongest indicator of recurrence. These data provide an important insight to recurrence rates of genital warts before HPV vaccination and underline the significance of a long-term follow-up and HPV vaccination.
Identifiants
pubmed: 31286210
doi: 10.1007/s00404-019-05242-5
pii: 10.1007/s00404-019-05242-5
pmc: PMC6694085
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
661-668Références
J Gynecol Surg. 1995 Spring;11(1):41-50
pubmed: 10150437
J Clin Microbiol. 1999 Oct;37(10):3316-22
pubmed: 10488198
Acta Obstet Gynecol Scand. 2001 Dec;80(12):1121-4
pubmed: 11846709
Clin Infect Dis. 2002 Oct 15;35(Suppl 2):S210-24
pubmed: 12353208
Obstet Gynecol. 2003 Apr;101(4):645-52
pubmed: 12681865
Dermatol Online J. 2006 Mar 30;12(3):5
pubmed: 16638419
Obstet Gynecol Surv. 2006 Jun;61(6 Suppl 1):S3-14
pubmed: 16729902
Br J Dermatol. 2007 Mar;156(3):516-20
pubmed: 17300242
J Infect Dis. 2007 Nov 15;196(10):1447-54
pubmed: 18008222
Eur J Dermatol. 2008 Mar-Apr;18(2):153-8
pubmed: 18424374
BMC Infect Dis. 2008 Jun 02;8:76
pubmed: 18518976
J Infect Dis. 2009 Mar 15;199(6):805-14
pubmed: 19199546
Sex Transm Dis. 2009 Jun;36(6):380-6
pubmed: 19556932
Int J STD AIDS. 2009 Aug;20(8):557-60
pubmed: 19625588
J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e263-70
pubmed: 22409368
BMJ. 2013 Apr 18;346:f2032
pubmed: 23599298
Eur J Dermatol. 2013 Nov-Dec;23(6):837-42
pubmed: 24192222
BMC Public Health. 2013 Nov 12;13:1065
pubmed: 24215264
Lancet Infect Dis. 2015 May;15(5):565-80
pubmed: 25744474
Clin Infect Dis. 2015 Dec 15;61 Suppl 8:S849-55
pubmed: 26602622
CA Cancer J Clin. 2016 Sep;66(5):375-85
pubmed: 27434803
Sex Transm Dis. 2017 Nov;44(11):700-706
pubmed: 28876315
J Infect Dis. 2017 Dec 5;216(10):1205-1209
pubmed: 28968800
Genitourin Med. 1985 Feb;61(1):59-61
pubmed: 3936774
J Reprod Med. 1985 Jun;30(6):489-92
pubmed: 4020791
Am J Obstet Gynecol. 1984 Jan 1;148(1):9-12
pubmed: 6419610
Recent Results Cancer Res. 1993;133:105-11
pubmed: 8296056
J Infect Dis. 1997 Apr;175(4):743-8
pubmed: 9086125
Sex Transm Dis. 1997 Nov;24(10):567-72
pubmed: 9383844
Sex Transm Dis. 1998 Jul;25(6):285-92
pubmed: 9662761